High Levels of MeCP2 Depress MHC Class I Expression in Neuronal Cells

Julie Miralvès1, Eddy Magdeleine1, Lara Kaddoum1, Hélène Brun2, Sophie Peries1, Etienne Joly1∗

1 Institut de Pharmacologie et Biologie Structurale, Centre National de la Recherche Scientifique (CNRS), Toulouse, France, 2 Centre de Physiopathologie Toulouse-Purpan, INSERM, Toulouse, France

Background. The expression of MHC class I genes is repressed in mature neurons. The molecular basis of this regulation is poorly understood, but the genes are particularly rich in CpG islands. MeCP2 is a transcriptional repressor that binds to methylated CpG dinucleotides; mutations in this protein also cause the neurodevelopmental disease called Rett syndrome. Because MHC class I molecules play a role in neuronal connectivity, we hypothesised that MeCP2 might repress MHC class I expression in the CNS and that this might play a role in the pathology of Rett syndrome. Methodology. We show here that transiently transfected cells expressing high levels of MeCP2 specifically downregulate cell-surface expression of MHC class I molecules in the neuronal cell line N2A and they prevent the induction of MHC class I expression in response to interferon in these cells, supporting our first hypothesis. Surprisingly, however, overexpression of the mutated forms of MeCP2 that cause Rett syndrome had a similar effect on MHC class I expression as the wild-type protein. Immunohistological analyses of brain slices from MECP2 knockout mice (the MeCP2tm3.1bird strain) demonstrated a small but reproducible increase in MHC class I when compared to their wild type littermates, but we found no difference in MHC class I expression in primary cultures of mixed glial cells (mainly neurons and astrocytes) from the knockout and wild-type mice. Conclusion. These data suggest that high levels of MeCP2, such as those found in mature neurons, may contribute to the repression of MHC expression, but we find no evidence that MeCP2 regulation of MHC class I is important for the pathogenesis of Rett syndrome.

INTRODUCTION

Mutations in the X-linked gene MECP2 cause Rett syndrome (RTT) [1–3], a progressive neurodevelopmental disorder that affects around 1 in 10,000 female births [4]. Girls with RTT develop normally until 6–18 months old, when they begin to regress, losing the speech and hand skills they had acquired. Most patients develop severe mental retardation, seizures, repetitive hand movements, irregular breathing and motor-control problems [5–7]. MECP2 encodes the methyl-CpG-binding protein 2 (MeCP2) [8,9], which is thought to regulate gene expression, but we do not yet understand how mutations in this protein produce the pathological features of RTT.

MECP2 knockout mice [10–12] and mice expressing a truncated form of MeCP2 [13] display a RTT-like phenotype, demonstrating that MeCP2 deficiency is sufficient to induce the syndrome. Moreover, mice in which MECP2 was conditionally deleted in neurons had a similar phenotype to RTT patients [10,14], and MeCP2-deficient mice were cured by expression of a transgenic MECP2 gene specifically in post-mitotic neurons [15]. These findings indicate that the pathology of RTT is due to the lack of MeCP2 in the mature central nervous system (CNS). Two recent studies have shown that the neurological defects in mutant mice are reversed by restoration of MeCP2 expression in neurons, even at late postnatal stages [16,17], suggesting that gene therapy may be feasible.

The MECP2 mRNA is alternatively spliced to generate two protein isoforms (MeCP2A and MeCP2B) that differ at their N-terminal. Both forms are expressed ubiquitously, but MeCP2B is more abundant than MeCP2A in the CNS [18,19]. MeCP2 represses transcription [20] by binding through its methyl-CpG-binding domain (MBD) [21] to methylated CpG nucleotides [22,23] and recruiting co-repressors that bind to its transcription repression domain (TRD) [24–27]. Other studies, however, indicate that MeCP2 is a multifunctional protein that affects gene regulation at many levels: MeCP2 interacts with an RNA-binding protein called Y box-binding protein 1 to regulate splicing of target RNAs [28,29]; two studies suggest that MeCP2 influences gene expression by participating in chromatin architecture, independently of its capacity to bind methylated DNA [30,31]; moreover, MeCP2 associates with the DNA methyltransferase Dnmt1 bound to hemi-methylated DNA and may thus participate in maintaining the methylation state of newly synthesised DNA [32,33].

Our knowledge of the activities of MeCP2 suggests that the pathologies associated with MECP2 mutations are most likely due to the misregulation of neuronal genes. Several studies have identified possible target genes that are controlled by MeCP2, including the gene encoding brain-derived neurotrophic factor (BDNF) [34–36], genes encoding inhibitors of differentiation [37], and genes regulated by glucocorticoids [38]; their expression is altered in MECP2 knockout mice, but whether this is responsible for the neuropathology seen in RTT remains questionable.

We hypothesised that genes encoding MHC class I molecules (MHC class I) might be amongst those that MeCP2 regulates in

...
Overexpression of MeCP2 downregulates basal MHC class I

To investigate whether MeCP2 represses MHC class I expression, we transiently transfected mouse neuronal cell line N2A with pCMX vectors encoding the Myc-tagged version of human MeCP2A or MeCP2B. Forty-eight hours after transfection, we evaluated by flow cytometry the cell surface levels of Kk, Ld, and Dd (three ‘classical’ MHC class I molecules). We observed that, in these transfected cells, cells expressing high levels of MeCP2 (dotted circle, Figure 1D) had less MHC class I on their surface than cells expressing MeCP2 at lower levels (continuous circle). The same was true for cells overexpressing human MeCP2A or MeCP2B, but the levels of protein expressed by these cells was relatively low (at best comparable to those in the continuous circle in Figure 1D). It is therefore of little surprise that the levels of MHC class I expressed by those cells was not discernibly different from that of untransfected cells (not shown). Evaluation by quantitative western blot of the levels of MeCP2 protein expressed in these various transfected cells revealed bands of comparable intensities in stable transfecants and in brain extracts, and bands that were two to five fold more intense in transiently transfected populations (not shown). Since mature neurons represent approximately 15% of all cells in the brain parenchyma, we can further estimate that our stable transfectants express levels of MHC class I which are roughly one sixth of those found in mature neurons. Conversely, since the efficiency of the transient transfections in this experiment was approximately 10%, we estimate that the levels of MHC class I attained in high expressors after transient transfections are 20 to 50 fold higher than the levels in stable transfectants (and therefore three to eight fold higher than in intra-cerebral neurons).

Overexpression of MeCP2 markedly reduces MHC class I upregulation by IFN-γ

The cytokine IFN-γ transactivates MHC class I expression predominantly by binding to IFN regulatory factor-1, which binds, in turn, to the interferon-stimulated response element, ISRE, a GC-rich region and therefore a potential binding site also for MeCP2 [47]. Since MeCP2 appeared to act as a repressor of MHC class I expression (Figure 1), we wanted to test whether it would interfere with transactivation of MHC class I expression by
IFN-γ. To do so, we transfected N2A cells with pCMX vectors driving the expression of either murine or human MeCP2A. The following day, these transiently transfected cells were divided into two flasks that were either treated or not with IFN-γ for 48 hrs. The levels of cell-surface MHC class I, β2-microglobulin and transferrin receptor, and intracellular MeCP2A, were evaluated by flow cytometry as in the previous experiments (Figure 2). As can be seen by the shift of the clouds between the higher and the lower panels, treatment with IFN-γ resulted in a two- to four-fold induction of MHC class I and β2-microglobulin in both mock-transfected populations and transfected populations (Figure 2A). Individual transfected cells expressing MeCP2A at high levels, however, had little more Ld and β2-microglobulin when treated with IFN-γ than untreated MeCP2A-expressing cells (compare the populations encircled in Figure 2A IFN-γ with those without IFN-γ). Cells overexpressing MeCP2A therefore appear to respond to IFN-γ by upregulating MHC class I to a much lesser extent than do cells not expressing MeCP2A.

The statistical significance of the differences in response to IFN-γ was confirmed for all three MHC class I molecules expressed by...
the N2A cell line (K^d, L^d, D^d) and for β2-microglobulin in six independent experiments (Figure 2B), whereas the levels of transferrin receptor were not significantly affected. This effect was also observed in other cell lines such as NIH 3T3 fibroblasts and human HEK 293 cells (not shown).

**MeCP2 mutants retain their repressive effect on MHC class I expression**

Many disease-causing mutations of MECP2 have been described [48]. Among them, some occur more frequently than others, and/or have been more thoroughly characterised. To investigate the effect of these MECP2 mutations on MHC class I expression, we transiently transfected the N2A cell line with plasmids expressing well-characterised mutants of both the A and B isoforms of MeCP2 (T158M, R133C, R306C and R308*). The point mutations T158M, R133C and R306C are located in the functional MBD and TRD domains of the protein (Figure 3A). The mutant form that is truncated after the R308 residue corresponds to the form of MeCP2 found in the mouse model of RTT generated by Dr. Zoghbi’s group [13]. We performed mutagenesis on vectors expressing either the A or B form of Myc-tagged MeCP2. All the mutated plasmids were sequenced and checked for functional expression and intracellular localisation of the wild-type and mutated MeCP2 proteins by anti-Myc immunofluorescence on transiently transfected N2A cells (Figure 3B). All the mutant forms of Myc-taged MeCP2 were located in intranuclear punctate structures typical of the wild-type protein, which forms foci on heterochromatin [22,49] (data is shown for the R133C MeCP2 A-Myc mutant and the wild-type pMeCP2 A-Myc protein only).

Subsequently, we evaluated the cell-surface expression level of MHC class I in the transiently transfected N2A cells by flow cytometry using the rat anti-pan-MHC I antibody M1/42, as before. The intracellular MeCP2 level was evaluated based on the intensity of immunostaining for the Myc tag, and was found to be similar to the wild-type for both the A and B forms of the four mutants. The R133C MeCP2 A-Myc mutant had the same effect as its wild-type counterpart on the cell-surface level of MHC class I (Figure 3C), whereas neither mutant nor wild type had a significant effect on expression of the transferrin receptor (not shown). Similar
effects were found for both A and B isoforms of all four mutants tested (Data for T158M R306C and R308* are not shown). Thus, these mutations responsible for RTT do not abolish the repressive effect of MeCP2 on MHC class I in cells in culture. These results strongly suggest that the repressive function of MeCP2 on the levels of MHC molecules expressed by transiently transfected cells in vitro is unlikely to be directly related to the pathogenesis of Rett syndrome.

Expression of MHC class I in cells from MeCP2-knockout mice is no different to that in cells from wild-type mice

Our data from experiments with cells in culture (above) suggest that the genes encoding MHC class I and β2-microglobulin are controlled by MeCP2; overexpression of normal MeCP2 down-regulates their expression. To find out whether this is the case in vivo, we investigated whether neuronal cells from MeCP2 knockout mice (MeCP2<sup>tm1.1Bird</sup>) contained elevated levels of MHC class I by performing immunohistochemistry on frozen brain sections of MECP2 knockout hemizygous male (-/y) mice and of their wild-type littermates using two different rat monoclonal antibodies directed against mouse MHC class I molecules. The results we obtained suggest that there are slightly higher levels of MHC class I expression in some regions of the brains of MeCP2 knockout mice than in the same regions of the wild-type control brains (Figure 4). Although these differences were not always seen for all brain areas of MECP2 knockout mice compared to their control littermates, when a difference was seen, it was always for higher expression in MECP2 knockout animals.

The immunohistochemistry approach did not allow us to quantify the small variations we observed in MHC class I expression between MeCP2 knockout and wild-type mice or to identify the cell types that expressed MHC class I in the absence of MeCP2 (neurons, astrocytes, oligodendrocytes or endothelial cells). We therefore decided to look at primary cultures of brain cells...
MeCP2 Reduces MHC I Expression

DISCUSSION

Reports by Shatz and colleagues [40,41,51] have demonstrated clearly that tight regulation of MHC class I genes in the CNS contributes to the establishment and maintenance of neuronal connections during development, as well as to plastic remodelling in the hippocampus and to neuronal signalling in specific areas of the brain [40,41,51]. We reasoned that the transcriptional repressor MeCP2 might be involved in regulating MHC class I expression in the CNS for three main reasons. Firstly, expression of MeCP2 is strictly regulated during development [52–54] and specifically in various cell types [55] and is highest in mature neurons [56,57], which do not express MHC class I. Secondly, MeCP2 binds to methylated cytidine residues on CpG dinucleotides [21] and the genes for MHC class I are particularly rich in C/G residues [39]. Thirdly, mutations in the MECP2 gene are responsible for the neurodevelopmental disorder RTT. We hypothesised that MeCP2 represses expression of MHC class I and that mutations responsible for RTT might cause the loss of this activity.

In support of the first part of this hypothesis, we showed clearly that overexpression of either of the two isoforms of MeCP2 by transient transfection of neuronal and fibroblastic cell lines results in reduced levels of MHC class I and β2-microglobulin at the cell surface. Furthermore, overexpression of MeCP2 blocked induction of MHC class I in these cells in response to IFN-γ. We could not determine whether this decreased expression of MHC class I and β2-microglobulin in response to MeCP2 overexpression was due to reduced transcription, translation or transport to the cell surface because the cells were transiently transfected; only cells that expressed high levels of MeCP2 showed reduced levels of MHC class I on their surface, so we could not quantify the levels of mRNA by RT-PCR or northern blot.

The fact that we observed very similar extents of repression of all three MHC class I forms (Kk, Ld and Dd) as well as of β2-microglobulin suggests that MeCP2 probably does not act directly on the promoters of the various loci encoding MHC class I, which are not identical. These considerations lead us to think that the effect of MeCP2 may be a more ‘global’, indirect mechanism than transcriptional repression by binding to methyl cytosine in the promoters.
The global decrease in cell surface MHC class I in MeCP2-expressing cells might be due to an effect on chromatin architecture encompassing the whole MHC region, which includes, in addition to the MHC class I loci, other genes involved in the assembly and transport of MHC molecules [58,59] that might contribute to a global effect. If MeCP2 condenses the chromatin in the MHC region, this might block access of transcription factors and regulatory factors to the genes, as suggested by the work of Georgel and colleagues [30]. Such chromatin condensation would also explain the failure of IFN-γ to induce MHC class I in cells overexpressing MeCP2 if it prevented IFN regulatory factors from binding to their response element.

Our findings that the MeCP2 forms mutated either in the MBD or TRD domains conserve their repressive effect on MHC class I expression strengthen this interpretation that MeCP2 has an indirect effect on transcription through its effect on chromatin architecture. These mutations affect only transcriptional repression by MeCP2, preventing it from binding to methylated DNA.

Figure 5. Deletion of MECP2 does not affect basal or IFN-γ-induced MHC class I expression in primary cultures of mixed glial cells. Mixed glial cell cultures established from two-day old wild-type, MeCP2+/− and MeCP2−/− mice (10, 6 and 8 animals per group, respectively) were treated or not with IFN-γ on the second day of culture and analysed two days later by flow cytometry for MHC class I expression. Neurons were identified by their intracellular staining with an anti-β-III-tubulin antibody (inset). Large cells, containing mainly astrocytes, were analysed separately by an appropriate forward/side scatter gate. Primary spleen fibroblasts from the same mice were also subjected or not to IFN-γ treatment and stained for their MHC class I expression. Panel A: Representative histograms showing cell surface staining (x axis) against cell number (y axis), obtained with cells from wild-type and MeCP2−/− male littermates. White-filled curves represent background staining, gray-filled curves represent MHC I-specific staining. Panel B: MHC class I fold-induction in response to IFN-γ was calculated as the ratio of MFI of treated cells (induced MHC I level) on MFI of untreated cells (basal MHC I level). Grey-filled squares show MHC class I fold-induction for individual mice and for each cell type. White-filled squares represent the group's mean of fold-inductions (± SD). doi:10.1371/journal.pone.0001354.g005
and from recruiting repressor partners, but the other functions of the protein are not affected, particularly its capacity to silence gene expression by driving chromatin condensation [30,60] and stabilising large silencing chromatin loops [31]. The ability of MeCP2 to condense chromatin by methylation-independent DNA binding relies on regions within the N-terminal 294 residues, distinct from the MBD [30,61].

MeCP2 induces chromatin condensation in three successive steps: first, it binds to the linker DNA between nucleosomes; second, it brings the nucleosomes together in a ‘stem conformation’ through DNA–protein interactions, and third, it binds to the nucleosomes themselves to produce full chromatin compaction [60]. Whereas the C-terminal region of MeCP2 is dispensable for the two first steps, it is apparently required for maximal compaction of the chromatin since the R294X mutation abolishes bridging between nucleosomes [60,61]. By contrast, the R133C mutation, which abolishes the selective recognition of methylated DNA, retains the chromatin compaction properties of the wild-type protein [30]. The two other point mutations we tested in this study, T158M and R306C, like R133C, may retain their compaction properties and thus their repressive effect on MHC genes. Our findings with the truncated form R306*, which also retains the same repressive effect on MHC class I expression as the wild-type protein, indicate that the repression of MHC genes by MeCP2 does not involve the C-terminal portion of the protein. The effects of MeCP2 on MHC expression therefore probably does not involve the third step of MeCP2-induced chromatin condensation (above) but may involve a conformational change in the ‘stem organization’ of the chromatin around the MHC region [60,61].

If MeCP2 represses MHC class I expression, we expected to see elevated levels of MHC class I in the brains of MeCP2 knockout mice (strain MeCP2<sup>tm1.Bird</sup>) when compared to mice with fully functional MECP2 [11]. When we stained brain slices immunohistochemically with two different antibodies, we saw a small but reproducible increase in MHC class I expression in the brains of three knockout male mice when compared to those of their wild-type littermates, but these results were purely qualitative, and it was not possible to quantify these differences by immunohistochemistry. We decided, therefore, to produce primary cultures of MGCs from knockout mice in order to quantify MHC class I expression by flow cytometry. This approach also allowed us to distinguish a neuronal population, comprised of small cells expressing βIII-tubulin, and a population of large cells comprising mostly of astrocytes. This quantitative analysis detected no difference between MHC class I levels on the surface of cells derived from animals carrying an inactivated MECP2 gene and those from their wild-type littermates whether for the basal level of MHC class I expression or for the level induced by IFN-γ. This was true for the neuronal population and the astrocyte population, as well as for primary cultures of spleen fibroblasts.

We conclude from these studies that there may be a small quantitative increase in MHC class I in the brains of MeCP2 knockout mice when compared to the wild type but this increase is not seen in isolated primary MGCs containing mostly neurons and astrocytes. The possibility remains that the levels of MeCP2 in these primary cell cultures were insufficient to see a difference. Indeed, our experiments with N2A cells showed that relatively high levels of MeCP2 are necessary to observe its repressive effect on MHC class I expression. Several studies have shown a direct correlation between age and MeCP2 expression, with maximal levels of expression in post-mitotic mature and differentiated neurons [52,53,55–57,62]. Although the neuronal populations in our MGCs expressed βIII-tubulin, a marker of neuronal differentiation, they were very probably far from being fully mature. In support of this, we were unable to detect MeCP2 expression in neonatal MGCs by flow cytometry (not shown). The neurons that we analysed in neonate MGC might therefore have been too immature to demonstrate a defect in MHC regulation due to MeCP2 deficiency. It was, however, not feasible to obtain brain tissue from adult MECP2 knockout animals for these studies because the mice die at around eight weeks old.

Three groups have performed transcriptome analyses on microarrays of cDNA prepared from post-mortem brain tissue of girls with RTT and from the brains of MECP2 knockout mice [63–65]. At least one of these studies supports the idea that MeCP2 may influence MHC expression in the CNS: Colantuoni et al. [63] found a 5.8-fold increase in expression of the mRNA for the MHC class I molecule HLA-A in a RTT syndrome patient relative to matched controls. This small increase in MHC class I expression in the absence of MeCP2 is consistent with our hypothesis and further suggests that such subtle disregulation might be detectable only in older mice than those we used in our study.

We found that the forms of MeCP2 carrying RTT-causing mutations retained their repressive function on MHC expression in transiently transfected cells. Although this observation does not go against our findings that MeCP2 can down-regulate MHC expression in cells where it is expressed at high levels, these results lead us to conclude that repression of MHC class I expression by MeCP2 is very probably not directly relevant to the pathogenesis of RTT. Mutations in the MECP2 gene are also suspected to be at the origin of a large panel of other neurological diseases such as autism [66,67], Angelman syndrome [68], X-linked mental retardation [69,70], and severe neonatal encephalopathy [71,72]. It may therefore be that those types of mutations responsible for other diseases could be related to the MHC-regulating activity of MeCP2. Additionally, the majority of MECP2 mutations in RTT are loss-of-function mutations, but overexpression of MECP2 by gene duplication in a mouse model [73], as well as in human clinical cases [74–77], also causes mental retardation and progressive neurological diseases. Since high levels of MeCP2 can repress cell surface expression of MHC class I, at least in neuronal cell lines, MeCP2 overexpression might result in an overexpression of MHC gene expression in the CNS, which may contribute to certain pathologies by preventing MHC molecules from fulfilling their roles during CNS development and in synaptic plasticity [51]. Inappropriate temporal and spatial repression of MHC genes by overexpressed MeCP2 might induce defects in neuronal functions similar to those observed in β2m/TAP1 deficient mice [41]. Further experiments will be required to explore this eventuality.

This leaves us with the important conclusion that high levels of MeCP2, like those found in mature neurons, repress expression of MHC class I molecules and this may be an important physiological factor contributing to the repression of MHC class I in the CNS.

**MATERIALS AND METHODS**

**Mice**
The MECP2 knockout mice (MeCP2<sup>tm1.Bird</sup>) were obtained from the Institute for Stem Cell Research, Edinburgh, UK. These mice have a RTT-like progressive neurodevelopmental disease very similar to that seen in patients; the males (♂/♀) suffer from a much more severe form of the disease than the heterozygous (♀/♂) females, and are sterile. MeCP2<sup>−/−</sup> female mice were mated with C57BL/6 male mice purchased from the Centre de Recherche et d’Élevage, Janvier, France. The litters obtained were genotyped initially as recommended by the Jackson Laboratory, and later with an optimised set of primers [78]. All experiments involving
animals were performed in compliance with the relevant laws and institutional guidelines.

Cell lines

The N2A and NIH 3T3 cell lines were maintained in DMEM with 10% foetal calf serum (FCS) and antibiotics. For the origin and description of these cell lines see ATCC.

Antibodies

Polyclonal primary antibodies: rabbit anti-MeCP2 polyclonal IgG (Upstate), mouse anti- C terminal peptide of MeCP2 (Sigma) and rabbit anti-beta III-tubulin polyclonal IgG (Abcam).

 Hybridoma supernatants from clones (obtained from ATCC): 9E10 (mouse anti-myc IgG1), M1/42 (rat anti-H2 IgG2a), R1-21.2 (rat anti-mouse H2 IgG2a), HB25 (mouse anti-H2 Kk IgG2a), 28.14.8 (mouse anti-H2 Dk, Lb and Dk IgG2a), 30.5.7 (mouse anti-H2 Lb, Db and Lb IgG2a), 34.4.20 (mouse anti-H2 Dd IgG2a), Y-3 (mouse anti-H2 Rk IgG2a), S19.8 (mouse anti-beta 2 microglobulin b and c IgG2a), R17.217 (rat anti-mouse transferrin receptor IgG2a).

Secondary fluorescent antibodies: FITC goat anti-mouse IgG (Dako), fluorescein goat anti-rabbit IgG (H+L) (Molecular Probes, Invitrogen), AlexaFluor 647 goat anti-rat IgG (H+L) (Molecular Probes, Invitrogen), AlexaFluor 647 and 680 goat anti-mouse IgG (H+L) (Molecular Probes, Invitrogen).

Plasmids

pCMX vectors expressing mouse MeCP2α, MeCP2β and human MeCP24 were described previously [18,79]. pcDNA3.1(A) vectors expressing Myc-tagged human MeCP24 and MeCP2B [19] were provided by Dr. Berge A. Minassian of the Hospital for Sick Children, Toronto, Ontario, Canada.

Mutagenesis

Site-directed mutagenesis of pcDNA3.1(A) vectors driving expression of Myc-tagged human MeCP24 and MeCP2B was carried out as described previously [80]. Briefly, during a first PCR reaction typically [9× (95°C for 30 s, 55°C for 1 min, 68°C for 1 min)] using high-fidelity Taq polymerase (Invitrogen), a DNA template was generated between a forward T7 oligonucleotide (5’-GTAATACGACTCACTATAG-3’) annealing to pcDNA3.1 (A) upstream of the multiple cloning site and a reverse oligonucleotide annealing to the MeCP2 sequence and carrying the chosen mutations:

R133C: 5’-aataccaacctcttactgacaaggttcctttctg-3’
T158M: 5’-ccctctccacgtatcatagatgaaataact-3’
R306C: 5’-ggtgcagcagccttcagctttgagggcagagag-3’

These primers were designed to produce or remove a restriction enzyme site allowing simple screening of the recovered plasmids. The amplified MeCP2 sequence was digested with XcmI and XbaI and ligated, using T4 DNA ligase (NEB), into pcDNA3.1 human MeCP24 or B myc-tagged plasmids digested with the same enzymes. The plasmids expressing truncated Myc-tagged MeCP24 and B forms were recovered by transforming competent DH5α bacteria and they were screened by restriction digestion. The sequence of the inserts corresponding to the MeCP2/R308* open reading frame was then checked by direct sequencing.

Transfection

Transfections were carried out using FuGENE 6 (Roche Applied Bioscience), following the manufacturer’s instructions (using 2 μg of plasmid and 6 μl of transfection reagent). Briefly, N2A or NIH 3T3 cells were plated in 25 cm² flasks at least 12 hrs before transfection. Stable N2A transfectants expressing Myc-tagged wild-type and mutated MeCP24 and MeCP2B were selected by adding 0.5 mg/ml of G418 three days after transfection, and the populations obtained were subsequently maintained in this selecting medium.

Quantitative Western Blot

Whole cellular extracts from adult mouse brain, and from transiently and stably transfected N2A cells were prepared, and blotted on nitrocellulose after separation by 4–12% SDS-PAGE (50 μg of cellular extract per sample). Levels of MeCP2 were then measured on an Odyssey infrared scanner (Li-Cor) after staining with a mouse anti-MeCP2 polyclonal antibody (C terminal portion, Sigma), followed by an Alexa 680 anti-mouse secondary antibody. Normalisation between samples was carried out using a mouse monoclonal against GAPDH (ab9484, abcam) and the same secondary reagent on the lower part of the same blot.

Cells staining and cytometry

For immunochecmical staining of the cell surface for MHC class I, β-2-microglobulin or transferrin receptor, cells were harvested by trypsinisation and washed once with medium to obtain a single-cell suspension. The resuspended cells were then incubated on ice with a saturating concentration of the appropriate hybridoma supernatant. Thirty minutes later, cells were washed three times in phosphate-buffered saline (PBS) containing 2% FCS, then incubated for thirty minutes on ice with the suitable secondary reagent and washed three times before fixation in PBS containing 1% paraformaldehyde. When intracellular MeCP2 or β-III-tubulin was also analysed, further staining steps were performed as described above, but adding 0.3% saponin in all buffers. Labelled cells were analysed using a FACS Calibur cytometer and CellQuest software (BD Biosciences). Dead cells were excluded using appropriate forward/side scatter gates.

Immunohistochemistry of brain slices

Brains from adult MeCP2+/− and wild-type mice were embedded in Tissue-Tek OCT compound (Sakura) and frozen in dry ice-cold
isopentane. Serial coronal sections of 10 μm were cut with a cryostat at −20°C, placed on Super Frost Plus slides (Menzel-Gläser), air dried overnight at room temperature and fixed in acetone and air dried rapidly. The tissue sections were then rehydrated in PBS containing 3% bovine serum albumin (BSA) and endogenous peroxidase activity was quenched by incubating with peroxidase block reagent (Dako). Following washes in PBS containing 1% BSA, the specimens were incubated with saturating concentrations of rat hybridoma supernatant for 1 hr and then rinsed in PBS containing 1% BSA before incubation with the rabbit anti-rat Ig antibody Z0494 (Dako). The sections were then treated with EnVision as instructed by the manufacturer (Dako) using a labelled polymer-HRP goat anti-rabbit Ig. Finally, slides were mounted in Mowiol. Observation and image acquisitions were carried out on a Leica RM-IRB microscope using the 10× objective. Pictures were taken with a COHU CCD camera.

**Immunofluorescence staining**

N2A cells growing on coverslips were transfected with empty pcDNA3.1(+), with pcDNA3.1 expressing Myc-tagged wild-type MeCP2 or B, or pcDNA3.1 expressing Myc-tagged mutated MeCP2 or B containing the T158M, R135C, R306C or R308* mutations. Cells were fixed with acetone and incubated with mouse anti-Myc monoclonal antibody (9E10) followed by FITC-labelled anti-mouse IgG antibody for 30 min at room temperature. After the final wash, the coverslips were mounted in DAPI-containing ProLong Gold antifading reagent (Molecular Probes). Observation and image acquisition were carried out on a Leica RM-IRB microscope using 40× or 20× objectives. Pictures were taken with a COHU CCD camera and acquired as TIFF stacks of images with Q-Fluoro software, after integration of the signal for 1 sec for in the case of FITC labelling (no integration of the signal for DAPI labelling).

**REFERENCES**

1. Amir RE, Van den Veyver IB, Watan M, Tran CQ, Francke U, et al. (1999) Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 23: 185–188.

2. Siriani N, Naidu S, Pereira J, Pilotto RF, Hoffman EP (1998) Rett syndrome: confirmation of X-linked dominant inheritance, and localization of the gene to Xq28. Am J Hum Genet 63: 1552–1558.

3. Bienvenu T, Carrie A, de Roux N, Vinet MC, Jonveaux P, et al. (2000) MECP2 mutations account for most cases of typical forms of Rett syndrome. Hum Mol Genet 9: 1377–1384.

4. Percy AK (2002) Rett syndrome. Current status and new vistas. Neurol Clin 20: 1125–1141.

5. Hagberg B, Acardi J, Dias K, Ramos O (1983) A progressive syndrome of autism, dementia, ataxia, and loss of purposive hand use in girls: Rett's syndrome: report of 35 cases. Ann Neurol 14: 471–479.

6. Neul JL, Zoghbi HY (2004) Rett syndrome: a prototypical neurodevelopmental disorder. Neuroscientist 10: 118–128.

7. Zoghbi HY (2005) MeCP2 dysfunction in humans and mice. J Child Neurol 20: 736–740.

8. Quaderi NA, Meehan RR, Tate PH, Cross SH, Bird AP, et al. (1994) Genetic and physical mapping of a gene encoding a methyl CpG binding protein, MeCP2, to the mouse X chromosome. Genomics 22: 640–651.

9. D’Esposito M, Quaderi NA, Caccioccola A, Bruni P, Esposito T, et al. (1996) Isolation, physical mapping, and northern analysis of the X-linked human gene encoding methyl CpG-binding protein, MECP2. Mammo Genome 7: 533–535.

10. Chen RZ, Akbarian S, Todorov M, Jarvik R (2001) Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet 27: 327–331.

11. Guy J, Hendrich B, Holmes M, Martin JE, Bird A (2001) A mouse MeCP2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet 27: 322–326.

12. Pelka GJ, Watson CM, Radziejewski T, Hayward M, Lahooti H, et al. (2006) MeCP2 deficiency is associated with learning and cognitive deficits and altered gene activity in the hippocampal region of mice. Brain 129: 107–191.

13. Shahbazian M, Young J, Yuva-Paylor I, Spencer C, Antalffy B, et al. (2002) Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron 35: 245–254.

14. Gemelli T, Berton O, Nelson ED, Perrotti LI, Jaenisch R, et al. (2006) Postnatal loss of methyl-CpG binding protein 2 in the forebrain is sufficient to mediate behavioral aspects of Rett syndrome in mice. Biol Psychiatry 59: 468–476.

15. Luikenhuis S, Giacometti E, Beard CF, Jaenisch R (2004) Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice. Proc Natl Acad Sci U S A 101: 6033–6038.

16. Giacometti E, Luikenhuis S, Beard C, Jaenisch R (2007) Partial rescue of MeCP2 deficiency by postnatal activation of MeCP2. Proc Natl Acad Sci U S A 104: 1931–1936.

17. Guy J, Gaj, Selfridge J, Cobb S, Bird A (2007) Reversal of neurological defects in a mouse model of Rett syndrome. Science 315: 1143–1147.

18. Kriaucionis S, Bird A (2004) The major form of MeCP2 has a novel N-terminus generated by alternative splicing. Nucleic Acids Res 32: 1018–1023.

19. Minzaazakian GN, Lohi H, Munteanu I, Alfred SE, Yamada T, et al. (2004) A previously unidentified MECP2 open reading frame defines a new protein isoform relevant to Rett syndrome. Nat Genet 36: 339–341.

20. Nan X, Campey EJ, Bird A (1997) MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 88: 471–481.

21. Nan X, Meehan RR, Bird A (1993) Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. Nucleic Acids Res 21: 4806–4812.

22. Nan X, Tate P, Li E, Bird A (1996) DNA methylation specifies chromosomal localization of MeCP2. Mol Cell Biol 16: 414–421.

23. Kloes RJ, Sarraf SA, Schiedelberg L, McDermott SM, Stanchova I, et al. (2005) DNA binding specificity of MeCP2 due to a requirement for A/T sequences adjacent to methyl-CpG. Mol Cell 19: 667–678.

24. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, et al. (1996) Transcriptional repression by the methyl-CpG binding protein MeCP2 involves a histone deacetylase complex. Nature 393: 386–389.

25. Jones PL, Veentra GJ, Wade PA, Vermaak D, Kass SU, et al. (1998) Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19: 107–107.

26. Kaludov NK, Wolffe AP (2000) MeCP2 driven transcriptional repression in vitro: selectivity for methylated DNA, action at a distance and contacts with the basal transcription machinery. Nucleic Acids Res 28: 1921–1928.

**MeCP2 Reduces MHC I Expression**

**Primary cultures**

Brains removed from two-day old mice were cut in small pieces in ice-cold PBS containing glucose, then centrifuged at 80 g for 5 min at 4°C and digested with trypsin (Gibco) for 40 min at 37°C. The trypsin was blocked by adding DMEM supplemented with 10% FCS for 5 min at room temperature. The digested brain material was then washed twice with DMEM containing 10% FCS and once in neurobasal medium (Gibco) supplemented with B27 and 2% FCS, and recovered between washes by centrifugation at 80 g for 5 min at 4°C. During the final wash, mechanical dissociation of the cells into a single-cell suspension was achieved by pipetting up and down several times. Brain cell suspensions were plated on six-well plates coated at least 12 hrs before with poly-D-ornithine (SIGMA) and maintained in neurobasal medium containing B27 and 2% FCS.

For cultures of splenic fibroblasts, spleens were cut into small pieces in PBS/glucose, digested in trypsin and washed, as above, and finally plated on six-well plates and maintained in RPMI containing 10% FCS.

**ACKNOWLEDGMENTS**

We would like to thank Dr. Brian Hendrich for his gift of reagents and helpful discussions, Drs Berge Minassian, and Adrian Bird for their gifts of plasmids, Denis Hudrisier and Jean Charles Guéry for helpful suggestions and discussions, and Carol Featherstone for her help with the manuscript.

**Author Contributions**

Conceived and designed the experiments: EJ JM. Performed the experiments: EM JM LK SP HB. Analyzed the data: EJ JM LK SP. Wrote the paper: EJ JM.
53. Cohen DR, Matarazzo V, Palmer AM, Tu Y, Jeon OH, et al. (2003) Expression of neural and non-neural genes in developing and mature CNS by neural activity. Neuron 21: 505–520.

54. Huh GS, Boulanger LM, Du H, Riquelme PA, Brotz TM, et al. (2000) Functional requirement for class I MHC in CNS development and plasticity. Science 290: 2153–2159.

55. Colantuoni C, Jeon OH, Hyder K, Chenchik A, Khimani AH, et al. (2001) MeCP2-reduces MHC I expression and patient classification. Neurobiol Dis 8: 847–856.

56. Beyer KS, Blasi F, Bacchelli E, Klauck SM, Maestrini E, et al. (2002) Mutation detection of the MECP2 region is a frequent cause of severe mental retardation detected by array CGH. J Med Genet 43: 362–370.

57. Collins AL, Levenson JM, Vilaythong AP, Richman R, Armstrong DL, et al. (2004) Real-time quantitative PCR as a routine method for screening large rearrangements in MeCP2. Hum Mol Genet 13: 115–124.

58. Baxi R, Ebert JT, Trottier LM, Westfall RM, Nagaraja HN, et al. (2005) MeCP2-chromatin interactions include the formation of chromatosome-like structures and are altered in mutations causing Rett syndrome. J Biol Chem 280: 4806–4812.

59. York IA, Rock KL (1996) Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 14: 369–396.

60. Nikitina T, Shi X, Ghosh RP, Horowitz-Schererr RA, Hansen JC, et al. (2007) Multiple modes of interaction between the methylated DNA binding protein MeCP2 and chromatin. Mol Cell Biol 27: 864–877.

61. Nikitina T, Ghosh RP, Horowitz-Schererr RA, Hansen JC, Grigoriev SA, et al. (2007) MeCP2-chromatin interactions include the formation of chromatosome-like structures and are altered in mutations causing Rett syndrome. J Biol Chem..

62. Balmer D, Goldstine J, Rao YM, LaSalle JM (2003) Elevated methyl-CpG-binding protein 2 expression is acquired during postnatal human brain development and is correlated with alternative polyadenylation. J Mol Med 81: 61–68.

63. Colantuoni C, Jeon OH, Hyder K, Chenchik AH, Khimani AH, et al. (2001) Gene expression profiling in postmortem Rett Syndrome brain: differential gene expression and patient classification. Neurobiol Dis 8: 847–856.

64. Tudor M, Akbarian S, Chen RZ, Jarnisch R (2002) Transcriptional profiling of a mouse model for Rett syndrome reveals subtle transcriptional changes in the brain. Proc Natl Acad Sci U S A 99: 15536–15541.

65. Traynor J, Agarwal P, Lazzaroni L, Francke U (2002) Gene expression patterns vary in clonal cell cultures from Rett syndrome females with eight different MECP2 mutations. BMC Med Genet 3: 12.

66. Lamp CW, Yeung WL, Ko CH, Poon PM, Tong SF, et al. (2000) Spectrum of mutations in the MECP2 gene in patients with infantile autism and Rett syndrome. J Med Genet 37: E41.

67. Beyer KS, Blasi F, Bacchelli E, Klauck M, Maestrini E, et al. (2002) Transcriptional profiling of a mouse model for Rett syndrome reveals subtle transcriptional changes in the brain. Proc Natl Acad Sci U S A 99: 15536–15541.

68. Couvert P, Bienvenu T, Aquaviva C, Poirier K, Moraine C, et al. (2001) MeCP2 is highly mutated in X-linked mental retardation. Hum Mol Genet 10: 941–946.

69. Clayton-Smith J, Watson P, Ramsden S, Black GC (2000) Somatic mutation in MECP2 as a non-fatal neurodevelopmental disorder in males. Lancet 356: 830–832.

70. Villard L, Kpebe A, Cardoso C, Chelly PJ, Tardieu PM, et al. (2000) Two affected boys in a Rett syndrome family: clinical and molecular findings. Neurology 55: 1188–1193.

71. Collins A, Levenson JM, Vilaythong A, Richman R, Armstrong DL, et al. (2004) Mild overexpression of MECP2 causes a progressive neurological disorder in mice. Hum Mol Genet 13: 2679–2689.

72. Ariani F, Mazi F, Pescucci G, Longo I, Bruttini M, et al. (2004) Real-time quantitative PCR as a routine method for screening large rearrangements in Rett syndrome: Report of one case of MECP2 deletion and one case of MECP2 duplication. Hum Mutat 24: 172–177.

73. Meins M, Lehmann J, Grether-Fiebig H, Herchenbach J, Hagendorn M, et al. (2005) Submicroscopic duplication in Xq28 causes increased expression of the MECP2 gene in a boy with severe mental retardation and features of Rett Syndrome. J Med Genet 42: e12.

74. Van Esch H, Bauters M, Ignatius J, Jansen M, Raynaud M, et al. (2005) Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. Am J Hum Genet 77: 442–453.

75. Leistnerberg D, de Brummer AP, Kleefstra T, Oudakker AR, Frints SG, et al. (2006) Chromosomal copy number changes in patients with non-syndromic X-linked mental retardation detected by array CGH. J Med Genet 43: 362–370.

76. Miralles J, Mageledane E, Joly E (2005) Design of an improved set of oligonucleotide primers for genotyping the MECP2/1.Bird KO mice by PCR. Mol Neurodegener 2: 16.

77. Heidrich B, Bird A (1996) Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol Cell Neurosci 22: 417–429.

78. Mullaney BC, Johnston MV, Blake ME (2000) Developmental expression of methyl-CpG binding protein 2 is dynamically regulated in the rodent brain. Neuroscience 125: 939–949.

79. Hendrich B, Bird A (1996) Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol Cell Neurosci 22: 417–429.